Global Peptide API CDMO Services Market Growth (Status and Outlook) 2026-2032
The global Peptide API CDMO Services market size is predicted to grow from US$ 3879 million in 2025 to US$ 14031 million in 2032; it is expected to grow at a CAGR of 19.8% from 2026 to 2032.
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
LPI (LP Information)' newest research report, the ?Peptide API CDMO Services Industry Forecast? looks at past sales and reviews total world Peptide API CDMO Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide API CDMO Services sales for 2026 through 2032. With Peptide API CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide API CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Peptide API CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide API CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Peptide API CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide API CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide API CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide API CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Peptide API CDMO Services refer to outsourced development and manufacturing services for therapeutic peptide active pharmaceutical ingredients, typically covering discovery-scale synthesis, process development, analytical development and validation, quality studies, regulatory support, GMP scale-up, and commercial supply, with peptide drug substance rather than finished dosage forms as the primary deliverable. The upstream supply base mainly includes protected and specialty amino acids, solid-phase synthesis resins, coupling reagents, cleavage and deprotection reagents, organic solvents such as acetonitrile, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotech firms, peptide generic and specialty drug developers, and manufacturers that formulate the API into injectable or other finished products. The 2025 gross margin of this segment showed wide dispersion because profitability depends heavily on development-stage mix, capacity utilization, commercial-scale execution, and process complexity; a realistic industry range is about 20%-55%, with development-heavy and high-value projects generally delivering higher margins, while platforms in large-scale ramp-up or major capacity expansion phases tend to report lower margins.
The peptide API CDMO services market is shifting from an outsourcing model centered mainly on early-stage development programs to a more integrated model covering process development, regulatory support, clinical supply, and commercial manufacturing. As peptide therapeutics continue to attract strong industry attention in metabolic disease, cardiovascular disease, oncology, and other chronic indications, customer requirements are becoming much more demanding. Buyers are no longer focused only on basic synthesis capability, but are placing greater emphasis on scale-up execution, impurity control, quality system maturity, and reliable long-term supply. For service providers, the ability to support a smooth transition from development to commercialization has become a critical part of market competitiveness.
On the supply side, the industry is moving toward greater scale, stronger platform integration, and more refined manufacturing capabilities. Peptide API production requires high standards in route design, purification efficiency, yield control, solvent management, and batch consistency, which is why leading companies continue to invest in production facilities, analytical capabilities, green process technologies, and quality management systems. At the same time, customers are paying closer attention to multi-region supply assurance and efficient technology transfer, making service providers with multi-site operations, solid validation experience, and strong engineering capability better positioned to win late-stage programs and long-term partnerships.
On the demand side, the market is being driven primarily by the continued expansion of peptide drug pipelines, the ramp-up of marketed products, and the increasing willingness of pharmaceutical and biotech companies to outsource complex molecule development and manufacturing. More innovators are relying on specialized CDMO platforms to reduce capital intensity, shorten development timelines, and lower execution risk during scale-up. In parallel, the growing use of long-acting designs, molecular modifications, and higher-complexity peptide structures is raising customer expectations for process expertise, regulatory support, and commercial manufacturing experience, creating broader opportunities for providers with strong end-to-end capabilities.
At the same time, the market still faces meaningful constraints and operational challenges. Peptide API manufacturing depends heavily on key raw materials, resins, coupling systems, purification media, and highly disciplined quality infrastructure, so supply chain volatility and cost pressure can easily affect manufacturing performance. In addition, although capacity expansion remains active across the industry, new facilities must still go through validation, ramp-up, customer qualification, and commercial transition before their value can be fully realized. Companies that fall short in process robustness, environmental and safety compliance, global regulatory readiness, or operational efficiency may struggle to convert new capacity into sustainable growth. In the future, competition will be determined not simply by scale, but by how well companies balance technical depth, project execution, quality assurance, delivery resilience, and cost control.
LPI (LP Information)' newest research report, the ?Peptide API CDMO Services Industry Forecast? looks at past sales and reviews total world Peptide API CDMO Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide API CDMO Services sales for 2026 through 2032. With Peptide API CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide API CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Peptide API CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide API CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Peptide API CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide API CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide API CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide API CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
- GMP Services
- Non-GMP Services
- SPPS
- LPPS
- Hybrid Technology
- Small-Scale (mg?g)
- Medium-Scale (g?kg)
- Large-Scale (kg?t)
- Commercial
- Scientific Research
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- PolyPeptide (CH)
- Bachem (CH)
- AmbioPharm (US)
- CordenPharma (CH)
- CPC Scientific (US)
- Piramal Pharma Solutions (IN)
- Almac Group (UK)
- Aspen API (ZA)
- Neuland Laboratories (IN)
- USV (IN)
- Aurigene Pharmaceutical Services (IN)
- PeptiStar (JP)
- BCN Peptides (ES)
- Creative Peptides (US)
- Space Peptides (CH)
- Cambrex (US)
- Nippon Shokubai (JP)
- ScinoPharm (TW)
- ChengDu ShengNuo Biotec (CN)
- WuXi TIDES (CN)
- Asymchem (CN)
- Medtide (CN)
- Jiuzhou Pharma (CN)
- Hybio Pharmaceutical (CN)
- JYMed Peptide (CN)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide API CDMO Services Market Size (2021-2032)
2.1.2 Peptide API CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Peptide API CDMO Services by Country/Region (2021, 2025 & 2032)
2.2 Peptide API CDMO Services Segment by Type
2.2.1 GMP Services
2.2.2 Non-GMP Services
2.2.3 Peptide API CDMO Services Market Size by Type
2.2.3.1 Peptide API CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
2.3 Peptide API CDMO Services Segment by Synthesis Technology
2.3.1 SPPS
2.3.2 LPPS
2.3.3 Hybrid Technology
2.3.4 Peptide API CDMO Services Market Size by Synthesis Technology
2.3.4.1 Peptide API CDMO Services Market Size CAGR by Synthesis Technology (2021 VS 2025 VS 2032)
2.3.4.2 Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2026)
2.4 Peptide API CDMO Services Segment by Capacity Tier
2.4.1 Small-Scale (mg?g)
2.4.2 Medium-Scale (g?kg)
2.4.3 Large-Scale (kg?t)
2.4.4 Peptide API CDMO Services Market Size by Capacity Tier
2.4.4.1 Peptide API CDMO Services Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032)
2.4.4.2 Global Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2026)
2.5 Peptide API CDMO Services Segment by Application
2.5.1 Commercial
2.5.2 Scientific Research
2.5.3 Other
2.5.4 Peptide API CDMO Services Market Size by Application
2.5.4.1 Peptide API CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
3 PEPTIDE API CDMO SERVICES MARKET SIZE BY PLAYER
3.1 Peptide API CDMO Services Market Size Market Share by Player
3.1.1 Global Peptide API CDMO Services Revenue by Player (2021-2026)
3.1.2 Global Peptide API CDMO Services Revenue Market Share by Player (2021-2026)
3.2 Global Peptide API CDMO Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE API CDMO SERVICES BY REGION
4.1 Peptide API CDMO Services Market Size by Region (2021-2026)
4.2 Global Peptide API CDMO Services Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide API CDMO Services Market Size Growth (2021-2026)
4.4 APAC Peptide API CDMO Services Market Size Growth (2021-2026)
4.5 Europe Peptide API CDMO Services Market Size Growth (2021-2026)
4.6 Middle East & Africa Peptide API CDMO Services Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Peptide API CDMO Services Market Size by Country (2021-2026)
5.2 Americas Peptide API CDMO Services Market Size by Type (2021-2026)
5.3 Americas Peptide API CDMO Services Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide API CDMO Services Market Size by Region (2021-2026)
6.2 APAC Peptide API CDMO Services Market Size by Type (2021-2026)
6.3 APAC Peptide API CDMO Services Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide API CDMO Services Market Size by Country (2021-2026)
7.2 Europe Peptide API CDMO Services Market Size by Type (2021-2026)
7.3 Europe Peptide API CDMO Services Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide API CDMO Services by Region (2021-2026)
8.2 Middle East & Africa Peptide API CDMO Services Market Size by Type (2021-2026)
8.3 Middle East & Africa Peptide API CDMO Services Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE API CDMO SERVICES MARKET FORECAST
10.1 Global Peptide API CDMO Services Forecast by Region (2027-2032)
10.1.1 Global Peptide API CDMO Services Forecast by Region (2027-2032)
10.1.2 Americas Peptide API CDMO Services Forecast
10.1.3 APAC Peptide API CDMO Services Forecast
10.1.4 Europe Peptide API CDMO Services Forecast
10.1.5 Middle East & Africa Peptide API CDMO Services Forecast
10.2 Americas Peptide API CDMO Services Forecast by Country (2027-2032)
10.2.1 United States Market Peptide API CDMO Services Forecast
10.2.2 Canada Market Peptide API CDMO Services Forecast
10.2.3 Mexico Market Peptide API CDMO Services Forecast
10.2.4 Brazil Market Peptide API CDMO Services Forecast
10.3 APAC Peptide API CDMO Services Forecast by Region (2027-2032)
10.3.1 China Peptide API CDMO Services Market Forecast
10.3.2 Japan Market Peptide API CDMO Services Forecast
10.3.3 Korea Market Peptide API CDMO Services Forecast
10.3.4 Southeast Asia Market Peptide API CDMO Services Forecast
10.3.5 India Market Peptide API CDMO Services Forecast
10.3.6 Australia Market Peptide API CDMO Services Forecast
10.4 Europe Peptide API CDMO Services Forecast by Country (2027-2032)
10.4.1 Germany Market Peptide API CDMO Services Forecast
10.4.2 France Market Peptide API CDMO Services Forecast
10.4.3 UK Market Peptide API CDMO Services Forecast
10.4.4 Italy Market Peptide API CDMO Services Forecast
10.4.5 Russia Market Peptide API CDMO Services Forecast
10.5 Middle East & Africa Peptide API CDMO Services Forecast by Region (2027-2032)
10.5.1 Egypt Market Peptide API CDMO Services Forecast
10.5.2 South Africa Market Peptide API CDMO Services Forecast
10.5.3 Israel Market Peptide API CDMO Services Forecast
10.5.4 Turkey Market Peptide API CDMO Services Forecast
10.6 Global Peptide API CDMO Services Forecast by Type (2027-2032)
10.7 Global Peptide API CDMO Services Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Peptide API CDMO Services Forecast
11 KEY PLAYERS ANALYSIS
11.1 PolyPeptide (CH)
11.1.1 PolyPeptide (CH) Company Information
11.1.2 PolyPeptide (CH) Peptide API CDMO Services Product Offered
11.1.3 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 PolyPeptide (CH) Main Business Overview
11.1.5 PolyPeptide (CH) Latest Developments
11.2 Bachem (CH)
11.2.1 Bachem (CH) Company Information
11.2.2 Bachem (CH) Peptide API CDMO Services Product Offered
11.2.3 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Bachem (CH) Main Business Overview
11.2.5 Bachem (CH) Latest Developments
11.3 AmbioPharm (US)
11.3.1 AmbioPharm (US) Company Information
11.3.2 AmbioPharm (US) Peptide API CDMO Services Product Offered
11.3.3 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 AmbioPharm (US) Main Business Overview
11.3.5 AmbioPharm (US) Latest Developments
11.4 CordenPharma (CH)
11.4.1 CordenPharma (CH) Company Information
11.4.2 CordenPharma (CH) Peptide API CDMO Services Product Offered
11.4.3 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CordenPharma (CH) Main Business Overview
11.4.5 CordenPharma (CH) Latest Developments
11.5 CPC Scientific (US)
11.5.1 CPC Scientific (US) Company Information
11.5.2 CPC Scientific (US) Peptide API CDMO Services Product Offered
11.5.3 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 CPC Scientific (US) Main Business Overview
11.5.5 CPC Scientific (US) Latest Developments
11.6 Piramal Pharma Solutions (IN)
11.6.1 Piramal Pharma Solutions (IN) Company Information
11.6.2 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product Offered
11.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Piramal Pharma Solutions (IN) Main Business Overview
11.6.5 Piramal Pharma Solutions (IN) Latest Developments
11.7 Almac Group (UK)
11.7.1 Almac Group (UK) Company Information
11.7.2 Almac Group (UK) Peptide API CDMO Services Product Offered
11.7.3 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Almac Group (UK) Main Business Overview
11.7.5 Almac Group (UK) Latest Developments
11.8 Aspen API (ZA)
11.8.1 Aspen API (ZA) Company Information
11.8.2 Aspen API (ZA) Peptide API CDMO Services Product Offered
11.8.3 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Aspen API (ZA) Main Business Overview
11.8.5 Aspen API (ZA) Latest Developments
11.9 Neuland Laboratories (IN)
11.9.1 Neuland Laboratories (IN) Company Information
11.9.2 Neuland Laboratories (IN) Peptide API CDMO Services Product Offered
11.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Neuland Laboratories (IN) Main Business Overview
11.9.5 Neuland Laboratories (IN) Latest Developments
11.10 USV (IN)
11.10.1 USV (IN) Company Information
11.10.2 USV (IN) Peptide API CDMO Services Product Offered
11.10.3 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 USV (IN) Main Business Overview
11.10.5 USV (IN) Latest Developments
11.11 Aurigene Pharmaceutical Services (IN)
11.11.1 Aurigene Pharmaceutical Services (IN) Company Information
11.11.2 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product Offered
11.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Aurigene Pharmaceutical Services (IN) Main Business Overview
11.11.5 Aurigene Pharmaceutical Services (IN) Latest Developments
11.12 PeptiStar (JP)
11.12.1 PeptiStar (JP) Company Information
11.12.2 PeptiStar (JP) Peptide API CDMO Services Product Offered
11.12.3 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 PeptiStar (JP) Main Business Overview
11.12.5 PeptiStar (JP) Latest Developments
11.13 BCN Peptides (ES)
11.13.1 BCN Peptides (ES) Company Information
11.13.2 BCN Peptides (ES) Peptide API CDMO Services Product Offered
11.13.3 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 BCN Peptides (ES) Main Business Overview
11.13.5 BCN Peptides (ES) Latest Developments
11.14 Creative Peptides (US)
11.14.1 Creative Peptides (US) Company Information
11.14.2 Creative Peptides (US) Peptide API CDMO Services Product Offered
11.14.3 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Creative Peptides (US) Main Business Overview
11.14.5 Creative Peptides (US) Latest Developments
11.15 Space Peptides (CH)
11.15.1 Space Peptides (CH) Company Information
11.15.2 Space Peptides (CH) Peptide API CDMO Services Product Offered
11.15.3 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Space Peptides (CH) Main Business Overview
11.15.5 Space Peptides (CH) Latest Developments
11.16 Cambrex (US)
11.16.1 Cambrex (US) Company Information
11.16.2 Cambrex (US) Peptide API CDMO Services Product Offered
11.16.3 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Cambrex (US) Main Business Overview
11.16.5 Cambrex (US) Latest Developments
11.17 Nippon Shokubai (JP)
11.17.1 Nippon Shokubai (JP) Company Information
11.17.2 Nippon Shokubai (JP) Peptide API CDMO Services Product Offered
11.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Nippon Shokubai (JP) Main Business Overview
11.17.5 Nippon Shokubai (JP) Latest Developments
11.18 ScinoPharm (TW)
11.18.1 ScinoPharm (TW) Company Information
11.18.2 ScinoPharm (TW) Peptide API CDMO Services Product Offered
11.18.3 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 ScinoPharm (TW) Main Business Overview
11.18.5 ScinoPharm (TW) Latest Developments
11.19 ChengDu ShengNuo Biotec (CN)
11.19.1 ChengDu ShengNuo Biotec (CN) Company Information
11.19.2 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product Offered
11.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 ChengDu ShengNuo Biotec (CN) Main Business Overview
11.19.5 ChengDu ShengNuo Biotec (CN) Latest Developments
11.20 WuXi TIDES (CN)
11.20.1 WuXi TIDES (CN) Company Information
11.20.2 WuXi TIDES (CN) Peptide API CDMO Services Product Offered
11.20.3 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 WuXi TIDES (CN) Main Business Overview
11.20.5 WuXi TIDES (CN) Latest Developments
11.21 Asymchem (CN)
11.21.1 Asymchem (CN) Company Information
11.21.2 Asymchem (CN) Peptide API CDMO Services Product Offered
11.21.3 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Asymchem (CN) Main Business Overview
11.21.5 Asymchem (CN) Latest Developments
11.22 Medtide (CN)
11.22.1 Medtide (CN) Company Information
11.22.2 Medtide (CN) Peptide API CDMO Services Product Offered
11.22.3 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Medtide (CN) Main Business Overview
11.22.5 Medtide (CN) Latest Developments
11.23 Jiuzhou Pharma (CN)
11.23.1 Jiuzhou Pharma (CN) Company Information
11.23.2 Jiuzhou Pharma (CN) Peptide API CDMO Services Product Offered
11.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Jiuzhou Pharma (CN) Main Business Overview
11.23.5 Jiuzhou Pharma (CN) Latest Developments
11.24 Hybio Pharmaceutical (CN)
11.24.1 Hybio Pharmaceutical (CN) Company Information
11.24.2 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product Offered
11.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Hybio Pharmaceutical (CN) Main Business Overview
11.24.5 Hybio Pharmaceutical (CN) Latest Developments
11.25 JYMed Peptide (CN)
11.25.1 JYMed Peptide (CN) Company Information
11.25.2 JYMed Peptide (CN) Peptide API CDMO Services Product Offered
11.25.3 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 JYMed Peptide (CN) Main Business Overview
11.25.5 JYMed Peptide (CN) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide API CDMO Services Market Size (2021-2032)
2.1.2 Peptide API CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Peptide API CDMO Services by Country/Region (2021, 2025 & 2032)
2.2 Peptide API CDMO Services Segment by Type
2.2.1 GMP Services
2.2.2 Non-GMP Services
2.2.3 Peptide API CDMO Services Market Size by Type
2.2.3.1 Peptide API CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
2.3 Peptide API CDMO Services Segment by Synthesis Technology
2.3.1 SPPS
2.3.2 LPPS
2.3.3 Hybrid Technology
2.3.4 Peptide API CDMO Services Market Size by Synthesis Technology
2.3.4.1 Peptide API CDMO Services Market Size CAGR by Synthesis Technology (2021 VS 2025 VS 2032)
2.3.4.2 Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2026)
2.4 Peptide API CDMO Services Segment by Capacity Tier
2.4.1 Small-Scale (mg?g)
2.4.2 Medium-Scale (g?kg)
2.4.3 Large-Scale (kg?t)
2.4.4 Peptide API CDMO Services Market Size by Capacity Tier
2.4.4.1 Peptide API CDMO Services Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032)
2.4.4.2 Global Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2026)
2.5 Peptide API CDMO Services Segment by Application
2.5.1 Commercial
2.5.2 Scientific Research
2.5.3 Other
2.5.4 Peptide API CDMO Services Market Size by Application
2.5.4.1 Peptide API CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
3 PEPTIDE API CDMO SERVICES MARKET SIZE BY PLAYER
3.1 Peptide API CDMO Services Market Size Market Share by Player
3.1.1 Global Peptide API CDMO Services Revenue by Player (2021-2026)
3.1.2 Global Peptide API CDMO Services Revenue Market Share by Player (2021-2026)
3.2 Global Peptide API CDMO Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE API CDMO SERVICES BY REGION
4.1 Peptide API CDMO Services Market Size by Region (2021-2026)
4.2 Global Peptide API CDMO Services Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide API CDMO Services Market Size Growth (2021-2026)
4.4 APAC Peptide API CDMO Services Market Size Growth (2021-2026)
4.5 Europe Peptide API CDMO Services Market Size Growth (2021-2026)
4.6 Middle East & Africa Peptide API CDMO Services Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Peptide API CDMO Services Market Size by Country (2021-2026)
5.2 Americas Peptide API CDMO Services Market Size by Type (2021-2026)
5.3 Americas Peptide API CDMO Services Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide API CDMO Services Market Size by Region (2021-2026)
6.2 APAC Peptide API CDMO Services Market Size by Type (2021-2026)
6.3 APAC Peptide API CDMO Services Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide API CDMO Services Market Size by Country (2021-2026)
7.2 Europe Peptide API CDMO Services Market Size by Type (2021-2026)
7.3 Europe Peptide API CDMO Services Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide API CDMO Services by Region (2021-2026)
8.2 Middle East & Africa Peptide API CDMO Services Market Size by Type (2021-2026)
8.3 Middle East & Africa Peptide API CDMO Services Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE API CDMO SERVICES MARKET FORECAST
10.1 Global Peptide API CDMO Services Forecast by Region (2027-2032)
10.1.1 Global Peptide API CDMO Services Forecast by Region (2027-2032)
10.1.2 Americas Peptide API CDMO Services Forecast
10.1.3 APAC Peptide API CDMO Services Forecast
10.1.4 Europe Peptide API CDMO Services Forecast
10.1.5 Middle East & Africa Peptide API CDMO Services Forecast
10.2 Americas Peptide API CDMO Services Forecast by Country (2027-2032)
10.2.1 United States Market Peptide API CDMO Services Forecast
10.2.2 Canada Market Peptide API CDMO Services Forecast
10.2.3 Mexico Market Peptide API CDMO Services Forecast
10.2.4 Brazil Market Peptide API CDMO Services Forecast
10.3 APAC Peptide API CDMO Services Forecast by Region (2027-2032)
10.3.1 China Peptide API CDMO Services Market Forecast
10.3.2 Japan Market Peptide API CDMO Services Forecast
10.3.3 Korea Market Peptide API CDMO Services Forecast
10.3.4 Southeast Asia Market Peptide API CDMO Services Forecast
10.3.5 India Market Peptide API CDMO Services Forecast
10.3.6 Australia Market Peptide API CDMO Services Forecast
10.4 Europe Peptide API CDMO Services Forecast by Country (2027-2032)
10.4.1 Germany Market Peptide API CDMO Services Forecast
10.4.2 France Market Peptide API CDMO Services Forecast
10.4.3 UK Market Peptide API CDMO Services Forecast
10.4.4 Italy Market Peptide API CDMO Services Forecast
10.4.5 Russia Market Peptide API CDMO Services Forecast
10.5 Middle East & Africa Peptide API CDMO Services Forecast by Region (2027-2032)
10.5.1 Egypt Market Peptide API CDMO Services Forecast
10.5.2 South Africa Market Peptide API CDMO Services Forecast
10.5.3 Israel Market Peptide API CDMO Services Forecast
10.5.4 Turkey Market Peptide API CDMO Services Forecast
10.6 Global Peptide API CDMO Services Forecast by Type (2027-2032)
10.7 Global Peptide API CDMO Services Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Peptide API CDMO Services Forecast
11 KEY PLAYERS ANALYSIS
11.1 PolyPeptide (CH)
11.1.1 PolyPeptide (CH) Company Information
11.1.2 PolyPeptide (CH) Peptide API CDMO Services Product Offered
11.1.3 PolyPeptide (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 PolyPeptide (CH) Main Business Overview
11.1.5 PolyPeptide (CH) Latest Developments
11.2 Bachem (CH)
11.2.1 Bachem (CH) Company Information
11.2.2 Bachem (CH) Peptide API CDMO Services Product Offered
11.2.3 Bachem (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Bachem (CH) Main Business Overview
11.2.5 Bachem (CH) Latest Developments
11.3 AmbioPharm (US)
11.3.1 AmbioPharm (US) Company Information
11.3.2 AmbioPharm (US) Peptide API CDMO Services Product Offered
11.3.3 AmbioPharm (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 AmbioPharm (US) Main Business Overview
11.3.5 AmbioPharm (US) Latest Developments
11.4 CordenPharma (CH)
11.4.1 CordenPharma (CH) Company Information
11.4.2 CordenPharma (CH) Peptide API CDMO Services Product Offered
11.4.3 CordenPharma (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CordenPharma (CH) Main Business Overview
11.4.5 CordenPharma (CH) Latest Developments
11.5 CPC Scientific (US)
11.5.1 CPC Scientific (US) Company Information
11.5.2 CPC Scientific (US) Peptide API CDMO Services Product Offered
11.5.3 CPC Scientific (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 CPC Scientific (US) Main Business Overview
11.5.5 CPC Scientific (US) Latest Developments
11.6 Piramal Pharma Solutions (IN)
11.6.1 Piramal Pharma Solutions (IN) Company Information
11.6.2 Piramal Pharma Solutions (IN) Peptide API CDMO Services Product Offered
11.6.3 Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Piramal Pharma Solutions (IN) Main Business Overview
11.6.5 Piramal Pharma Solutions (IN) Latest Developments
11.7 Almac Group (UK)
11.7.1 Almac Group (UK) Company Information
11.7.2 Almac Group (UK) Peptide API CDMO Services Product Offered
11.7.3 Almac Group (UK) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Almac Group (UK) Main Business Overview
11.7.5 Almac Group (UK) Latest Developments
11.8 Aspen API (ZA)
11.8.1 Aspen API (ZA) Company Information
11.8.2 Aspen API (ZA) Peptide API CDMO Services Product Offered
11.8.3 Aspen API (ZA) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Aspen API (ZA) Main Business Overview
11.8.5 Aspen API (ZA) Latest Developments
11.9 Neuland Laboratories (IN)
11.9.1 Neuland Laboratories (IN) Company Information
11.9.2 Neuland Laboratories (IN) Peptide API CDMO Services Product Offered
11.9.3 Neuland Laboratories (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Neuland Laboratories (IN) Main Business Overview
11.9.5 Neuland Laboratories (IN) Latest Developments
11.10 USV (IN)
11.10.1 USV (IN) Company Information
11.10.2 USV (IN) Peptide API CDMO Services Product Offered
11.10.3 USV (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 USV (IN) Main Business Overview
11.10.5 USV (IN) Latest Developments
11.11 Aurigene Pharmaceutical Services (IN)
11.11.1 Aurigene Pharmaceutical Services (IN) Company Information
11.11.2 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product Offered
11.11.3 Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Aurigene Pharmaceutical Services (IN) Main Business Overview
11.11.5 Aurigene Pharmaceutical Services (IN) Latest Developments
11.12 PeptiStar (JP)
11.12.1 PeptiStar (JP) Company Information
11.12.2 PeptiStar (JP) Peptide API CDMO Services Product Offered
11.12.3 PeptiStar (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 PeptiStar (JP) Main Business Overview
11.12.5 PeptiStar (JP) Latest Developments
11.13 BCN Peptides (ES)
11.13.1 BCN Peptides (ES) Company Information
11.13.2 BCN Peptides (ES) Peptide API CDMO Services Product Offered
11.13.3 BCN Peptides (ES) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 BCN Peptides (ES) Main Business Overview
11.13.5 BCN Peptides (ES) Latest Developments
11.14 Creative Peptides (US)
11.14.1 Creative Peptides (US) Company Information
11.14.2 Creative Peptides (US) Peptide API CDMO Services Product Offered
11.14.3 Creative Peptides (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Creative Peptides (US) Main Business Overview
11.14.5 Creative Peptides (US) Latest Developments
11.15 Space Peptides (CH)
11.15.1 Space Peptides (CH) Company Information
11.15.2 Space Peptides (CH) Peptide API CDMO Services Product Offered
11.15.3 Space Peptides (CH) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Space Peptides (CH) Main Business Overview
11.15.5 Space Peptides (CH) Latest Developments
11.16 Cambrex (US)
11.16.1 Cambrex (US) Company Information
11.16.2 Cambrex (US) Peptide API CDMO Services Product Offered
11.16.3 Cambrex (US) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Cambrex (US) Main Business Overview
11.16.5 Cambrex (US) Latest Developments
11.17 Nippon Shokubai (JP)
11.17.1 Nippon Shokubai (JP) Company Information
11.17.2 Nippon Shokubai (JP) Peptide API CDMO Services Product Offered
11.17.3 Nippon Shokubai (JP) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Nippon Shokubai (JP) Main Business Overview
11.17.5 Nippon Shokubai (JP) Latest Developments
11.18 ScinoPharm (TW)
11.18.1 ScinoPharm (TW) Company Information
11.18.2 ScinoPharm (TW) Peptide API CDMO Services Product Offered
11.18.3 ScinoPharm (TW) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 ScinoPharm (TW) Main Business Overview
11.18.5 ScinoPharm (TW) Latest Developments
11.19 ChengDu ShengNuo Biotec (CN)
11.19.1 ChengDu ShengNuo Biotec (CN) Company Information
11.19.2 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product Offered
11.19.3 ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 ChengDu ShengNuo Biotec (CN) Main Business Overview
11.19.5 ChengDu ShengNuo Biotec (CN) Latest Developments
11.20 WuXi TIDES (CN)
11.20.1 WuXi TIDES (CN) Company Information
11.20.2 WuXi TIDES (CN) Peptide API CDMO Services Product Offered
11.20.3 WuXi TIDES (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 WuXi TIDES (CN) Main Business Overview
11.20.5 WuXi TIDES (CN) Latest Developments
11.21 Asymchem (CN)
11.21.1 Asymchem (CN) Company Information
11.21.2 Asymchem (CN) Peptide API CDMO Services Product Offered
11.21.3 Asymchem (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Asymchem (CN) Main Business Overview
11.21.5 Asymchem (CN) Latest Developments
11.22 Medtide (CN)
11.22.1 Medtide (CN) Company Information
11.22.2 Medtide (CN) Peptide API CDMO Services Product Offered
11.22.3 Medtide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Medtide (CN) Main Business Overview
11.22.5 Medtide (CN) Latest Developments
11.23 Jiuzhou Pharma (CN)
11.23.1 Jiuzhou Pharma (CN) Company Information
11.23.2 Jiuzhou Pharma (CN) Peptide API CDMO Services Product Offered
11.23.3 Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Jiuzhou Pharma (CN) Main Business Overview
11.23.5 Jiuzhou Pharma (CN) Latest Developments
11.24 Hybio Pharmaceutical (CN)
11.24.1 Hybio Pharmaceutical (CN) Company Information
11.24.2 Hybio Pharmaceutical (CN) Peptide API CDMO Services Product Offered
11.24.3 Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Hybio Pharmaceutical (CN) Main Business Overview
11.24.5 Hybio Pharmaceutical (CN) Latest Developments
11.25 JYMed Peptide (CN)
11.25.1 JYMed Peptide (CN) Company Information
11.25.2 JYMed Peptide (CN) Peptide API CDMO Services Product Offered
11.25.3 JYMed Peptide (CN) Peptide API CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 JYMed Peptide (CN) Main Business Overview
11.25.5 JYMed Peptide (CN) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Peptide API CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Peptide API CDMO Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of GMP Services
Table 4. Major Players of Non-GMP Services
Table 5. Peptide API CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Table 8. Major Players of SPPS
Table 9. Major Players of LPPS
Table 10. Major Players of Hybrid Technology
Table 11. Peptide API CDMO Services Market Size CAGR by Synthesis Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Peptide API CDMO Services Market Size by Synthesis Technology (2021-2026) & ($ millions)
Table 13. Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2026)
Table 14. Major Players of Small-Scale (mg?g)
Table 15. Major Players of Medium-Scale (g?kg)
Table 16. Major Players of Large-Scale (kg?t)
Table 17. Peptide API CDMO Services Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Peptide API CDMO Services Market Size by Capacity Tier (2021-2026) & ($ millions)
Table 19. Global Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2026)
Table 20. Peptide API CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Table 23. Global Peptide API CDMO Services Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Peptide API CDMO Services Revenue Market Share by Player (2021-2026)
Table 25. Peptide API CDMO Services Key Players Head office and Products Offered
Table 26. Peptide API CDMO Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Table 31. Global Peptide API CDMO Services Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Peptide API CDMO Services Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Peptide API CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Peptide API CDMO Services Market Size Market Share by Country (2021-2026)
Table 35. Americas Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Table 37. Americas Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Table 39. APAC Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Table 41. APAC Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Peptide API CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Peptide API CDMO Services Market Size Market Share by Country (2021-2026)
Table 45. Europe Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Peptide API CDMO Services
Table 51. Key Market Challenges & Risks of Peptide API CDMO Services
Table 52. Key Industry Trends of Peptide API CDMO Services
Table 53. Global Peptide API CDMO Services Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Peptide API CDMO Services Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Peptide API CDMO Services Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Peptide API CDMO Services Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. PolyPeptide (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 58. PolyPeptide (CH) Peptide API CDMO Services Product Offered
Table 59. PolyPeptide (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. PolyPeptide (CH) Main Business
Table 61. PolyPeptide (CH) Latest Developments
Table 62. Bachem (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 63. Bachem (CH) Peptide API CDMO Services Product Offered
Table 64. Bachem (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Bachem (CH) Main Business
Table 66. Bachem (CH) Latest Developments
Table 67. AmbioPharm (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 68. AmbioPharm (US) Peptide API CDMO Services Product Offered
Table 69. AmbioPharm (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. AmbioPharm (US) Main Business
Table 71. AmbioPharm (US) Latest Developments
Table 72. CordenPharma (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 73. CordenPharma (CH) Peptide API CDMO Services Product Offered
Table 74. CordenPharma (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. CordenPharma (CH) Main Business
Table 76. CordenPharma (CH) Latest Developments
Table 77. CPC Scientific (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 78. CPC Scientific (US) Peptide API CDMO Services Product Offered
Table 79. CPC Scientific (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. CPC Scientific (US) Main Business
Table 81. CPC Scientific (US) Latest Developments
Table 82. Piramal Pharma Solutions (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 83. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product Offered
Table 84. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Piramal Pharma Solutions (IN) Main Business
Table 86. Piramal Pharma Solutions (IN) Latest Developments
Table 87. Almac Group (UK) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 88. Almac Group (UK) Peptide API CDMO Services Product Offered
Table 89. Almac Group (UK) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Almac Group (UK) Main Business
Table 91. Almac Group (UK) Latest Developments
Table 92. Aspen API (ZA) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 93. Aspen API (ZA) Peptide API CDMO Services Product Offered
Table 94. Aspen API (ZA) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Aspen API (ZA) Main Business
Table 96. Aspen API (ZA) Latest Developments
Table 97. Neuland Laboratories (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 98. Neuland Laboratories (IN) Peptide API CDMO Services Product Offered
Table 99. Neuland Laboratories (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Neuland Laboratories (IN) Main Business
Table 101. Neuland Laboratories (IN) Latest Developments
Table 102. USV (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 103. USV (IN) Peptide API CDMO Services Product Offered
Table 104. USV (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. USV (IN) Main Business
Table 106. USV (IN) Latest Developments
Table 107. Aurigene Pharmaceutical Services (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 108. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product Offered
Table 109. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Aurigene Pharmaceutical Services (IN) Main Business
Table 111. Aurigene Pharmaceutical Services (IN) Latest Developments
Table 112. PeptiStar (JP) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 113. PeptiStar (JP) Peptide API CDMO Services Product Offered
Table 114. PeptiStar (JP) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. PeptiStar (JP) Main Business
Table 116. PeptiStar (JP) Latest Developments
Table 117. BCN Peptides (ES) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 118. BCN Peptides (ES) Peptide API CDMO Services Product Offered
Table 119. BCN Peptides (ES) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. BCN Peptides (ES) Main Business
Table 121. BCN Peptides (ES) Latest Developments
Table 122. Creative Peptides (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 123. Creative Peptides (US) Peptide API CDMO Services Product Offered
Table 124. Creative Peptides (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Creative Peptides (US) Main Business
Table 126. Creative Peptides (US) Latest Developments
Table 127. Space Peptides (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 128. Space Peptides (CH) Peptide API CDMO Services Product Offered
Table 129. Space Peptides (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Space Peptides (CH) Main Business
Table 131. Space Peptides (CH) Latest Developments
Table 132. Cambrex (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 133. Cambrex (US) Peptide API CDMO Services Product Offered
Table 134. Cambrex (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Cambrex (US) Main Business
Table 136. Cambrex (US) Latest Developments
Table 137. Nippon Shokubai (JP) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 138. Nippon Shokubai (JP) Peptide API CDMO Services Product Offered
Table 139. Nippon Shokubai (JP) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Nippon Shokubai (JP) Main Business
Table 141. Nippon Shokubai (JP) Latest Developments
Table 142. ScinoPharm (TW) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 143. ScinoPharm (TW) Peptide API CDMO Services Product Offered
Table 144. ScinoPharm (TW) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. ScinoPharm (TW) Main Business
Table 146. ScinoPharm (TW) Latest Developments
Table 147. ChengDu ShengNuo Biotec (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 148. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product Offered
Table 149. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 150. ChengDu ShengNuo Biotec (CN) Main Business
Table 151. ChengDu ShengNuo Biotec (CN) Latest Developments
Table 152. WuXi TIDES (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 153. WuXi TIDES (CN) Peptide API CDMO Services Product Offered
Table 154. WuXi TIDES (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 155. WuXi TIDES (CN) Main Business
Table 156. WuXi TIDES (CN) Latest Developments
Table 157. Asymchem (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 158. Asymchem (CN) Peptide API CDMO Services Product Offered
Table 159. Asymchem (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 160. Asymchem (CN) Main Business
Table 161. Asymchem (CN) Latest Developments
Table 162. Medtide (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 163. Medtide (CN) Peptide API CDMO Services Product Offered
Table 164. Medtide (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 165. Medtide (CN) Main Business
Table 166. Medtide (CN) Latest Developments
Table 167. Jiuzhou Pharma (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 168. Jiuzhou Pharma (CN) Peptide API CDMO Services Product Offered
Table 169. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 170. Jiuzhou Pharma (CN) Main Business
Table 171. Jiuzhou Pharma (CN) Latest Developments
Table 172. Hybio Pharmaceutical (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 173. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product Offered
Table 174. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 175. Hybio Pharmaceutical (CN) Main Business
Table 176. Hybio Pharmaceutical (CN) Latest Developments
Table 177. JYMed Peptide (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 178. JYMed Peptide (CN) Peptide API CDMO Services Product Offered
Table 179. JYMed Peptide (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 180. JYMed Peptide (CN) Main Business
Table 181. JYMed Peptide (CN) Latest Developments
Table 1. Peptide API CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Peptide API CDMO Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of GMP Services
Table 4. Major Players of Non-GMP Services
Table 5. Peptide API CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Table 8. Major Players of SPPS
Table 9. Major Players of LPPS
Table 10. Major Players of Hybrid Technology
Table 11. Peptide API CDMO Services Market Size CAGR by Synthesis Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Peptide API CDMO Services Market Size by Synthesis Technology (2021-2026) & ($ millions)
Table 13. Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology (2021-2026)
Table 14. Major Players of Small-Scale (mg?g)
Table 15. Major Players of Medium-Scale (g?kg)
Table 16. Major Players of Large-Scale (kg?t)
Table 17. Peptide API CDMO Services Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Peptide API CDMO Services Market Size by Capacity Tier (2021-2026) & ($ millions)
Table 19. Global Peptide API CDMO Services Market Size Market Share by Capacity Tier (2021-2026)
Table 20. Peptide API CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Table 23. Global Peptide API CDMO Services Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Peptide API CDMO Services Revenue Market Share by Player (2021-2026)
Table 25. Peptide API CDMO Services Key Players Head office and Products Offered
Table 26. Peptide API CDMO Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Table 31. Global Peptide API CDMO Services Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Peptide API CDMO Services Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Peptide API CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Peptide API CDMO Services Market Size Market Share by Country (2021-2026)
Table 35. Americas Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Table 37. Americas Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Table 39. APAC Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Table 41. APAC Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Peptide API CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Peptide API CDMO Services Market Size Market Share by Country (2021-2026)
Table 45. Europe Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Peptide API CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Peptide API CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Peptide API CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Peptide API CDMO Services
Table 51. Key Market Challenges & Risks of Peptide API CDMO Services
Table 52. Key Industry Trends of Peptide API CDMO Services
Table 53. Global Peptide API CDMO Services Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Peptide API CDMO Services Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Peptide API CDMO Services Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Peptide API CDMO Services Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. PolyPeptide (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 58. PolyPeptide (CH) Peptide API CDMO Services Product Offered
Table 59. PolyPeptide (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. PolyPeptide (CH) Main Business
Table 61. PolyPeptide (CH) Latest Developments
Table 62. Bachem (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 63. Bachem (CH) Peptide API CDMO Services Product Offered
Table 64. Bachem (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Bachem (CH) Main Business
Table 66. Bachem (CH) Latest Developments
Table 67. AmbioPharm (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 68. AmbioPharm (US) Peptide API CDMO Services Product Offered
Table 69. AmbioPharm (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. AmbioPharm (US) Main Business
Table 71. AmbioPharm (US) Latest Developments
Table 72. CordenPharma (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 73. CordenPharma (CH) Peptide API CDMO Services Product Offered
Table 74. CordenPharma (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. CordenPharma (CH) Main Business
Table 76. CordenPharma (CH) Latest Developments
Table 77. CPC Scientific (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 78. CPC Scientific (US) Peptide API CDMO Services Product Offered
Table 79. CPC Scientific (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. CPC Scientific (US) Main Business
Table 81. CPC Scientific (US) Latest Developments
Table 82. Piramal Pharma Solutions (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 83. Piramal Pharma Solutions (IN) Peptide API CDMO Services Product Offered
Table 84. Piramal Pharma Solutions (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Piramal Pharma Solutions (IN) Main Business
Table 86. Piramal Pharma Solutions (IN) Latest Developments
Table 87. Almac Group (UK) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 88. Almac Group (UK) Peptide API CDMO Services Product Offered
Table 89. Almac Group (UK) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Almac Group (UK) Main Business
Table 91. Almac Group (UK) Latest Developments
Table 92. Aspen API (ZA) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 93. Aspen API (ZA) Peptide API CDMO Services Product Offered
Table 94. Aspen API (ZA) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Aspen API (ZA) Main Business
Table 96. Aspen API (ZA) Latest Developments
Table 97. Neuland Laboratories (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 98. Neuland Laboratories (IN) Peptide API CDMO Services Product Offered
Table 99. Neuland Laboratories (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Neuland Laboratories (IN) Main Business
Table 101. Neuland Laboratories (IN) Latest Developments
Table 102. USV (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 103. USV (IN) Peptide API CDMO Services Product Offered
Table 104. USV (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. USV (IN) Main Business
Table 106. USV (IN) Latest Developments
Table 107. Aurigene Pharmaceutical Services (IN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 108. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Product Offered
Table 109. Aurigene Pharmaceutical Services (IN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Aurigene Pharmaceutical Services (IN) Main Business
Table 111. Aurigene Pharmaceutical Services (IN) Latest Developments
Table 112. PeptiStar (JP) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 113. PeptiStar (JP) Peptide API CDMO Services Product Offered
Table 114. PeptiStar (JP) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. PeptiStar (JP) Main Business
Table 116. PeptiStar (JP) Latest Developments
Table 117. BCN Peptides (ES) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 118. BCN Peptides (ES) Peptide API CDMO Services Product Offered
Table 119. BCN Peptides (ES) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. BCN Peptides (ES) Main Business
Table 121. BCN Peptides (ES) Latest Developments
Table 122. Creative Peptides (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 123. Creative Peptides (US) Peptide API CDMO Services Product Offered
Table 124. Creative Peptides (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Creative Peptides (US) Main Business
Table 126. Creative Peptides (US) Latest Developments
Table 127. Space Peptides (CH) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 128. Space Peptides (CH) Peptide API CDMO Services Product Offered
Table 129. Space Peptides (CH) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Space Peptides (CH) Main Business
Table 131. Space Peptides (CH) Latest Developments
Table 132. Cambrex (US) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 133. Cambrex (US) Peptide API CDMO Services Product Offered
Table 134. Cambrex (US) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Cambrex (US) Main Business
Table 136. Cambrex (US) Latest Developments
Table 137. Nippon Shokubai (JP) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 138. Nippon Shokubai (JP) Peptide API CDMO Services Product Offered
Table 139. Nippon Shokubai (JP) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Nippon Shokubai (JP) Main Business
Table 141. Nippon Shokubai (JP) Latest Developments
Table 142. ScinoPharm (TW) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 143. ScinoPharm (TW) Peptide API CDMO Services Product Offered
Table 144. ScinoPharm (TW) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. ScinoPharm (TW) Main Business
Table 146. ScinoPharm (TW) Latest Developments
Table 147. ChengDu ShengNuo Biotec (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 148. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Product Offered
Table 149. ChengDu ShengNuo Biotec (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 150. ChengDu ShengNuo Biotec (CN) Main Business
Table 151. ChengDu ShengNuo Biotec (CN) Latest Developments
Table 152. WuXi TIDES (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 153. WuXi TIDES (CN) Peptide API CDMO Services Product Offered
Table 154. WuXi TIDES (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 155. WuXi TIDES (CN) Main Business
Table 156. WuXi TIDES (CN) Latest Developments
Table 157. Asymchem (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 158. Asymchem (CN) Peptide API CDMO Services Product Offered
Table 159. Asymchem (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 160. Asymchem (CN) Main Business
Table 161. Asymchem (CN) Latest Developments
Table 162. Medtide (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 163. Medtide (CN) Peptide API CDMO Services Product Offered
Table 164. Medtide (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 165. Medtide (CN) Main Business
Table 166. Medtide (CN) Latest Developments
Table 167. Jiuzhou Pharma (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 168. Jiuzhou Pharma (CN) Peptide API CDMO Services Product Offered
Table 169. Jiuzhou Pharma (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 170. Jiuzhou Pharma (CN) Main Business
Table 171. Jiuzhou Pharma (CN) Latest Developments
Table 172. Hybio Pharmaceutical (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 173. Hybio Pharmaceutical (CN) Peptide API CDMO Services Product Offered
Table 174. Hybio Pharmaceutical (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 175. Hybio Pharmaceutical (CN) Main Business
Table 176. Hybio Pharmaceutical (CN) Latest Developments
Table 177. JYMed Peptide (CN) Details, Company Type, Peptide API CDMO Services Area Served and Its Competitors
Table 178. JYMed Peptide (CN) Peptide API CDMO Services Product Offered
Table 179. JYMed Peptide (CN) Peptide API CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 180. JYMed Peptide (CN) Main Business
Table 181. JYMed Peptide (CN) Latest Developments
LIST OF FIGURES
Figure 1. Peptide API CDMO Services Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide API CDMO Services Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Peptide API CDMO Services Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Peptide API CDMO Services Sales Market Share by Country/Region (2025)
Figure 8. Peptide API CDMO Services Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Peptide API CDMO Services Market Size Market Share by Type in 2025
Figure 10. Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology in 2025
Figure 11. Global Peptide API CDMO Services Market Size Market Share by Capacity Tier in 2025
Figure 12. Peptide API CDMO Services in Commercial
Figure 13. Global Peptide API CDMO Services Market: Commercial (2021-2026) & ($ millions)
Figure 14. Peptide API CDMO Services in Scientific Research
Figure 15. Global Peptide API CDMO Services Market: Scientific Research (2021-2026) & ($ millions)
Figure 16. Peptide API CDMO Services in Other
Figure 17. Global Peptide API CDMO Services Market: Other (2021-2026) & ($ millions)
Figure 18. Global Peptide API CDMO Services Market Size Market Share by Application in 2025
Figure 19. Global Peptide API CDMO Services Revenue Market Share by Player in 2025
Figure 20. Global Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Figure 21. Americas Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 22. APAC Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 23. Europe Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 25. Americas Peptide API CDMO Services Value Market Share by Country in 2025
Figure 26. United States Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Peptide API CDMO Services Market Size Market Share by Region in 2025
Figure 31. APAC Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 32. APAC Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 33. China Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 37. India Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Peptide API CDMO Services Market Size Market Share by Country in 2025
Figure 40. Europe Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 41. Europe Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 42. Germany Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 43. France Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 56. APAC Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 57. Europe Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 59. United States Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 60. Canada Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 61. Mexico Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 62. Brazil Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 63. China Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 64. Japan Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 65. Korea Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 67. India Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 68. Australia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 69. Germany Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 70. France Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 71. UK Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 72. Italy Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 73. Russia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 74. Egypt Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 75. South Africa Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 76. Israel Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 77. Turkey Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 78. Global Peptide API CDMO Services Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Peptide API CDMO Services Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 1. Peptide API CDMO Services Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide API CDMO Services Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Peptide API CDMO Services Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Peptide API CDMO Services Sales Market Share by Country/Region (2025)
Figure 8. Peptide API CDMO Services Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Peptide API CDMO Services Market Size Market Share by Type in 2025
Figure 10. Global Peptide API CDMO Services Market Size Market Share by Synthesis Technology in 2025
Figure 11. Global Peptide API CDMO Services Market Size Market Share by Capacity Tier in 2025
Figure 12. Peptide API CDMO Services in Commercial
Figure 13. Global Peptide API CDMO Services Market: Commercial (2021-2026) & ($ millions)
Figure 14. Peptide API CDMO Services in Scientific Research
Figure 15. Global Peptide API CDMO Services Market: Scientific Research (2021-2026) & ($ millions)
Figure 16. Peptide API CDMO Services in Other
Figure 17. Global Peptide API CDMO Services Market: Other (2021-2026) & ($ millions)
Figure 18. Global Peptide API CDMO Services Market Size Market Share by Application in 2025
Figure 19. Global Peptide API CDMO Services Revenue Market Share by Player in 2025
Figure 20. Global Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Figure 21. Americas Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 22. APAC Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 23. Europe Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Peptide API CDMO Services Market Size 2021-2026 ($ millions)
Figure 25. Americas Peptide API CDMO Services Value Market Share by Country in 2025
Figure 26. United States Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Peptide API CDMO Services Market Size Market Share by Region in 2025
Figure 31. APAC Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 32. APAC Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 33. China Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 37. India Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Peptide API CDMO Services Market Size Market Share by Country in 2025
Figure 40. Europe Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 41. Europe Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 42. Germany Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 43. France Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Peptide API CDMO Services Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Peptide API CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 56. APAC Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 57. Europe Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 59. United States Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 60. Canada Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 61. Mexico Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 62. Brazil Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 63. China Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 64. Japan Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 65. Korea Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 67. India Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 68. Australia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 69. Germany Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 70. France Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 71. UK Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 72. Italy Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 73. Russia Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 74. Egypt Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 75. South Africa Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 76. Israel Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 77. Turkey Peptide API CDMO Services Market Size 2027-2032 ($ millions)
Figure 78. Global Peptide API CDMO Services Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Peptide API CDMO Services Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Peptide API CDMO Services Market Size 2027-2032 ($ millions)
